Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Net Cash Flow (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed Net Cash Flow for 16 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 48.89% to $2.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.8 million, a 15.95% decrease, with the full-year FY2025 number at $1.8 million, down 15.95% from a year prior.
  • Net Cash Flow was $2.7 million for Q4 2025 at Lemaitre Vascular, up from -$1.6 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $5.8 million in Q4 2023 to a low of -$4.2 million in Q2 2024.
  • A 5-year average of $114100.0 and a median of -$835000.0 in 2023 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: plummeted 411.44% in 2021, then surged 378.38% in 2022.
  • Lemaitre Vascular's Net Cash Flow stood at -$3.3 million in 2021, then surged by 146.37% to $1.6 million in 2022, then skyrocketed by 273.41% to $5.8 million in 2023, then decreased by 7.38% to $5.4 million in 2024, then crashed by 48.89% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for LMAT's Net Cash Flow are $2.7 million (Q4 2025), -$1.6 million (Q3 2025), and $1.2 million (Q2 2025).